Evidence map›Paper›PMID 37409096›Full record

ArticleProstate international2023

DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia.

Stephanie S Kim, Seung Cho Lee, Bumjin Lim, Seung-Ho Shin, Mee Young Kim, Sol-Yi Kim, Hyeyeun Lim, Clémentine Charton, Dongho Shin, Hyong Woo Moon and 4 more

Abstract read
In one paragraph

Article in Prostate international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Exploring the potential ofProstate international · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stephanie S KimPrecision Medicine Center, Future Innovation Research Division, Seoul National University Bundang Hospital, Seongnam, Korea.
Seung Cho LeeGENINUS Inc., Seoul, Korea.
Bumjin LimDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Seung-Ho ShinGENINUS Inc., Seoul, Korea.
Mee Young KimCancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sol-Yi KimGENINUS Inc., Seoul, Korea.
Hyeyeun LimGENINUS Inc., Seoul, Korea.
Clémentine ChartonPrecision Medicine Center, Future Innovation Research Division, Seoul National University Bundang Hospital, Seongnam, Korea.
Dongho ShinDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Hyong Woo MoonDepartment of Urology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jinho KimPrecision Medicine Center, Future Innovation Research Division, Seoul National University Bundang Hospital, Seongnam, Korea.
Donghyun ParkGENINUS Inc., Seoul, Korea.
Woong-Yang ParkGENINUS Inc., Seoul, Korea.
Ji Youl LeeCancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: DNA methylation markers are considered robust diagnostic features in various cancer types, as epigenetic marks are commonly altered during cancer progression. Differentiation between benign prostatic hyperplasia (BPH) and early-stage prostate cancer (PCa) is clinically difficult, relying on the information of the patient's symptoms or levels of prostate-specific antigen. Methods: A total of 42 PCa patients and 11 BPH patients were recruited. Genomic DNA was purified from tissues and used for the library preparation of the target-enriched methylome with enzymatic conversion and a Twist 85 Mbp EM-seq panel. Paired-end sequencing (150 bp) was performed using NovaSeq 6000 or NextSeq 550. After quality control, including adapter trimming and de-duplication of raw sequencing data, differential methylation patterns were analyzed between the BPH and PCa groups. Results: We report DNA methylation patterns existing between BPH and PCa. The major finding is that broad hypermethylation occurred at genic loci in PCa tissues as compared to the BPH. Gene ontology analysis suggested that hypermethylation of genic loci involved in chromatin and transcriptional regulation is involved in cancer progression. We also compared PCa tissues with high Gleason scores to tissues with low Gleason scores. The high-Gleason PCa tissues showed hundreds of focal differentially methylated CpG sites corresponding to genes functioning in cancer cell proliferation or metastasis. This suggests that dissecting early-to-advanced-grade cancer stages requires an in-depth analysis of differential methylation at the single CpG site level. Conclusions: Our study reports that enzymatic methylome sequencing data can be used to distinguish PCa from BPH and advanced PCa from early-stage PCa. The stage-specific methylation patterns in this study will be valuable resources for diagnostic purposes as well as further development of liquid biopsy approaches for the early detection of PCa.

Indexed as

Benign prostatic hyperplasiaBiomarkersCancer diagnosisDNA methylationEnzymatic conversionGleason scoreProstate cancerTarget enrichment sequencing

Identifiers

PMID37409096
PMCPMC10318333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.